Physical and social characteristics and support needs of adult female childhood cancer survivors who underwent hormone replacement therapy
AbstractBackgroundFemale childhood cancer survivors who develop gonadal dysfunction require female hormone replacement therapy (HRT) from puberty until menopause. However, the support provided in such cases has not been studied. We investigated the physical and social characteristics and support needs of adult female childhood cancer survivors who underwent HRT.MethodsForty-nine adult female childhood cancer survivors completed self-administered questionnaires. We compared the clinical characteristics, health status, and social conditions between a group that underwent HRT and a group that did not, and we surveyed support needs of the group that underwent HRT.ResultsThe median age of the subjects was 25.0 years (range 20−41). Twenty subjects (40.8%) underwent HRT. A significantly high number of those who underwent HRT also underwent radiation therapy (p
(MedPage Today) -- Peter Ubel, MD, explains how to let older patients know tests won't help
(MedPage Today) -- No higher risk of infant hospitalization, death linked to vaccines in pregnancy
A preplanned analysis of ctDNA found that a subpopulation of mCRC patients with acquired anti-EGFR resistance were sensitive to treatment with Sym004.
The addition of metronomic chemotherapy to dual HER2 blockade improved outcomes in older and frail patients with HER2-positive metastatic breast cancer.
Date: Wednesday, 03 21, 2018; Speaker: Charles Rabkin, M.D., Senior Investigator, Division of Cancer Epidemiology and Genetics, NCI; https://epi.grants.cancer.gov/events
Date: Thursday, 03 29, 2018; Speaker: Cassandra Harris, M.S., M.C.H.E.S., Manager, Health Education, MD Anderson Cancer Center; Kathi Ridley-Merriweather, M.A., Communications and Minority Outreach Coordinator, Komen Tissue Bank; Ren é Arnold, M.B.A., Former Operations Manager, The Fountain of Praise Church; https://epi.grants.cancer.gov/events/enrich-forum/
The Wayne D. Kuni&Joan E. Kuni Foundation has awarded $5 million to Legacy Health Foundation to found a cancer research project. The grant will fund research into how cancer can be targeted by manipulating adenosine kinase, an enzyme that controls cell growth. The research is led by Detlev Boison, Dow Chair of Neurology and director of neurobiology research and basic and translational research at Legacy Research Institute; and Dr. Serene Perkins, director of surgical and clinical research at…
Conclusions The majority of participants who had received ECT before age 18 years reported mild or absence of depression and anxiety on self-rated follow-up measures after treatment with ECT. Most notably, the majority reported absence of suicidality and adequate academic performance. A number of respondents, however, continued to endorse global impairment, which may be a reflection of their baseline severe illness, which had warranted treatment with ECT.
Conclusion: These findings demonstrate for the first time the molecular cascade and related cell biology events involved in the mechanism by which HGF and bFGF derived from hADSCs improved ovarian function during natural aging via reduction of oxidative stress by activating the SIRT1/FOXO1 signaling pathway.Cell Physiol Biochem 2018;45:1316 –1332
Cabozantinib showed significant antitumor activity in the treatment of differentiated thyroid cancer that progressed following surgery and radioactive iodine therapy, according to a new phase II study.